Axogen completed its previously announced acquisition of BioCircuit Technologies, a privately held medical-device company developing NerveTape, the first FDA-cleared sutureless device for repairing transected nerves. The company expects BioCircuit to contribute approximately $6 million in fourth-quarter 2026 revenue and approximately $34 million in 2027 revenue, amounts excluded from Axogen's latest full-year 2026 guidance of at least 24% revenue growth. Axogen continues to expect a gross margin of at least 73% and positive free cash flow for full-year 2026. BioCircuit develops devices for peripheral nerve repair and neuromodulation (technology for altering nerve activity), while Axogen plans to use its direct sales and hospital contracting capabilities to commercialize NerveTape. The expected benefits, including integration, adoption and financial results, remain subject to the risks outlined in Axogen's filings with the SEC (U.S. securities regulator).